For instance, in non-squamous NSCLC, KRAS mutation has been shown to interact with co-occurring mutations in TP53, STK11, PTPRD, RBM10, and ATM with respect to immune checkpoint inhibitor efficacy22. Here, KRAS is linked to non-small cell lung carcinoma.